Exagen
XGN | NASDAQ
$3.77
-$0.36 (-8.72%)
At close: Nov 16, 2026, 4:00 PM ET
$3.80
+$0.03 (+0.80%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-8.72%
(1D)No price chart data available for 1D timeframe.
Rating
36.8
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #622/1021 (Top 61%)
Key Statistics
Market Data
Market Cap $96.19M
1D Range
3.75 4.12
52W Range
2.65 8.74
Valuation (TTM)
PE -4.96
PB 6.98
EV/EBITDA -8.57
Valuation (NTM)
Forward PE N/A
Forward PEG 0.30
Price Target $9.50
Cash Flow
FCF Yield -13.5%
SBC Adj. FCF Yield -17.3%
SBC Impact -27.5%
Margins
Gross Margin 58.7%
Operating Margin -20.1%
FCF Margin -18.0%
Growth (CAGR)
Revenue 3Y | 5Y 11.9% |
8.4%
Dil EPS 3Y | 5Y 10.3% |
30.2%
FCF 3Y | 5Y -36.6% |
34.8%
Returns
ROA -32.8%
ROE -125.6%
ROIC -32.5%
Financial Health
Net Cash
$5.28M
Current Ratio 3.46
Interest Coverage -2.90
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the Uni...
Sector Healthcare
Industry Medical - Diagnostics & Research
Employees 216
IPO Date Sep 19, 2019
Website www.exagen.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$0.25
Miss -37.29%
YoY:
+19.35% REV
$18.42M
Beat +0.42%
YoY:
+6.80%Next Earnings
Mar 9, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
6
Consensus
Buy
Price Target
$9.50
Upside
+151.99%
Buy (6)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove XGN